Raymond James upgraded Stryker (SYK) to Outperform from Market Perform with a $418 price target The company has been one of the “highest quality compounders” in medical technology for the last five years, but the stock’s forward multiple compressed in 2025, as estimates trended higher, the analyst tells investors in a research note. Raymond James says this does not make sense. Stryker’s current valuation represents an attractive entry point, the firm contends.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target lowered to $390 from $405 at Evercore ISI
- Circle Internet initiated, Lyft downgraded: Wall Street’s top analyst calls
- Stryker upgraded to Outperform from Market Perform at Citizens
- Stryker price target lowered to $392 from $400 at Truist
- Stryker raises quarterly dividend to 88c per share